Table 1 Characteristics of the manufacturers
|  | Total (n = 39) | Group 1 (n = 21) | Group 2 (n = 11) | Group 3 (n = 7) |
|---|---|---|---|---|
Annual sales (million KRW) | ||||
   ~ 100,000 | 12 (30.8%) | 0 (0%) | 6 (54.5%) | 6 (85.7%) |
  100,000 ~ 300,000 | 13 (33.3%) | 7 (33.3%) | 5 (45.5%) | 1 (14.3%) |
  300,000 ~  | 14 (35.9%) | 14 (66.7%) | 0 (0%) | 0 (0%) |
Research and development intensity | ||||
  ~ 5% | 10 (25.6%) | 3 (14.3%) | 3 (27.3%) | 4 (57.1%) |
  5% ~ 7% | 10 (25.6%) | 6 (28.6%) | 2 (18.2%) | 2 (28.6%) |
  7% ~ 10% | 10 (25.6%) | 6 (28.6%) | 4 (36.4%) | 0 (0%) |
  10% ~  | 9 (23.1%) | 6 (28.6%) | 2 (18.2%) | 1 (14.3%) |
Designation as an innovative pharmaceutical manufacturer | ||||
  Yes | 14 (35.9%) | 12 (57.1%) | 2 (18.2%) | 0 (0%) |
  No | 25 (64.1%) | 9 (42.9%) | 9 (81.8%) | 7 (100%) |
Experience in developing new drugs | ||||
  Yes | 16 (41.0%) | 13 (61.9%) | 1 (9.1%) | 2 (28.6%) |
  No | 23 (59.0%) | 8 (38.1%) | 10 (90.9%) | 5 (71.4%) |
Experience in developing modified new drugs | ||||
  Yes | 27 (69.2%) | 17 (81.0%) | 7 (63.6%) | 3 (42.9%) |
  No | 12 (30.8%) | 4 (19.0%) | 4 (36.4%) | 4 (57.1%) |
Experience in granting first generic exclusivity after a successful patent challenge | ||||
  Yes | 30 (76.9%) | 19 (90.5%) | 11 (100%) | 0 (100%) |
  No | 9 (23.1%) | 2 (9.5%) | 0 (0%) | 7 (100%) |